Search Within

Department of Medicine

Formats
  1. Journal Article (19590)
  2. Meeting Abstract (16038)
  3. Review (1149)
  4. Book Section (934)
  5. Editorial (607)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22319)
  2. Hematologic Malignancies, Division of (13274)
  3. Center for Hematologic Malignancies (11058)
  4. GSK Faculty (10645)
  5. Survivorship Research (9329)
  6. Division of Subspecialty Medicine (7534)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1064)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4215)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2110)

More Publishers

Results (39615)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Obecabtagene autoleucel (obe-cel) for adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in the open-label, multi-center, global, single-arm, phase Ib/II FELIX study: The impact of bridging therapies on CAR T-cell expansion and persistence
    Meeting Abstract

    Park, J. H.; Jabbour, E.; Shaughnessy, P.; Logan, A. C.; Sandhu, K. S.; Abedi, M.; Shah, B. D.; Bishop, M. R.; Deangelo, D. J.; Lao-Sirieix, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Isatuximab in relapsed AL amyloidosis: Results of a prospective phase II trial (SWOG S1702)
    Meeting Abstract

    Parker, T. L.; Rosenthal, A.; Sanchorawala, V.; Landau, H.; Campagnaro, E. L.; Kapoor, P.; Neparidze, N.; Girnius, S.; Hagen, P.; Scott, E. C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Initial results of a phase 1 first-in-human study of cemsidomide (CFT7455), a novel MonoDACTM degrader, with dexamethasone in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Dhakal, B.; Yee, A. J.; Richardson, P. G.; Ailawadhi, S.; Chhabra, S.; Muchtar, E.; Berdeja, J. G.; Richard, S.; Matous, J.; Shah, U. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Uncovering the tumor antigen landscape in patients undergoing dendritic cell/myeloma fusion vaccine with lenalidomide maintenance treatment
    Meeting Abstract

    Karagkouni, D.; Cheloni, G.; Nanda, S.; Ma, Y. L.; Wang, S. S.; Katopodi, L. X.; Saldarriaga, I.; Pita-Juarez, Y.; Chung, D. J.; Shah, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase 1/2 studies of DZD8586, a non-covalent BBB penetrant LYN/BTK dual inhibitor, in BTK inhibitor resistant chronic lymphocytic Leukemia (CLL) and other B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Song, Y.; Zhou, K.; Jing, H.; Chong, G.; Wu, J.; Liu, W.; Li, Z.; Jiang, M.; Lan, M.; Ding, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A multi-center retrospective study on complex karyotype in patients with Richter transformation who received no chemoimmunotherapy for their CLL
    Meeting Abstract

    Miller, C.; Huang, Y.; Allan, J. N.; Bhat, S. A.; Bond, D. A.; Brander, D. M.; Byrd, J. C.; Chavez, J. C.; Chong, E. A.; Danilov, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Clinical outcomes and variability based on baseline cytogenetic risk of patients with MDS treated with hypomethylating agents: An analysis from the International Consortium for MDS (icMDS) validate database
    Meeting Abstract

    Getz, T. M.; Kewan, T.; Bewersdorf, J. P.; Stempel, J. M.; Lanino, L.; Wei, W.; Ali, N. H. A.; Dezern, A. E.; Sekeres, M. A.; Uy, G. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A Proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K. K.; Boardman, A. P.; Dahi, P. B.; Shah, G. L.; Scordo, M.; Park, J. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Five-year survival of patients (pts) from Transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M.; Wang, M.; Arnason, J. E.; Kamdar, M.; Maloney, D. G.; Shadman, M.; Andreadis, C.; more...
    Blood (2024)

    Fulltext@MSK | Save